Showing 464 results
-
Media Release /- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years- Xolair® is approved for CIU patients age…
-
Media Release /- Phase III data demonstrated Cosentyx resulted in clear or almost clear skin in the majority of patients with moderate-to-severe plaque psoriasis- Offering a new treatment option for patients,…
-
Media Release /- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints[1]- A statistically…
-
Media Release /In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NETApproval helps fulfill unmet need as progressive,…
-
Media Release /- Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the palms and soles of feet (palmoplantar) and nails- One third…
-
Media Release /The study met the primary endpoint with objective response rates of 41.8% and 32.5% respectively in the 200 mg and 800 mg treatment arms(1,2)Basal cell carcinoma is the most common form of skin…
-
Media Release /Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164…
-
Media Release /New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months…
-
Media Release /Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment EAST HANOVER, N.J., April 12, 2021…
-
Media Release /If approved, Xolair self-administration would offer a more flexible option to help select patients manage their treatment needs Filing acceptance is based on the well-established efficacy and…
